CX691
中文名称 | CX691 |
---|---|
中文同义词 | 化合物FARAMPATOR;苯并[C][1,2,5]恶二唑-5-基(哌啶-1-基)甲酮 |
英文名称 | FARAMPATOR |
英文同义词 | CX 691;Org 24448;FARAMPATOR;CX-691; ORG2444;Org2444;CX 691; ORG 24448; CX-691; CX691;Methanone, 2,1,3-benzoxadiazol-5-yl-1-piperidinyl-;Org24448, CX-691 |
CAS号 | 211735-76-1 |
分子式 | C12H13N3O2 |
分子量 | 231.25 |
EINECS号 | |
相关类别 | |
Mol文件 | 211735-76-1.mol |
结构式 |
CX691 性质
沸点 | 398.3±34.0 °C(Predicted) |
---|---|
密度 | 1.299±0.06 g/cm3(Predicted) |
储存条件 | Sealed in dry,Store in freezer, under -20°C |
溶解度 | DMF:30mg/mL; DMF:PBS(pH7.2)(1:40):25μg/ml;二甲基亚砜:20mg/mL |
形态 | 结晶固体 |
酸度系数(pKa) | -1.33±0.36(Predicted) |
颜色 | 白色至米白色 |
Farampator has potential in treating disorders characterised by cognitive deficits such as Alzheimer's disease and schizophrenia. CX691 attenuates a scopolamine-induced impairment of cued fear conditioning following acute administration (0.1 mg/kg p.o.) and a temporally induced deficit in novel object recognition following both acute (0.1 and 1.0 mg/kg p.o.) and sub-chronic (bi-daily for 7 days) administration (0.01, 0.03, 0.1 mg/kg p.o.). It also improves attentional set-shifting following sub-chronic administration (0.3 mg/kg p.o.). Farampator (500 mg) unequivocally improves short-term memory but appeares to impair episodic memory. Furthermore, it tends to decrease the number of switching errors in the CTMT. Drug-induced side effects (SEs) included headache, somnolence and nausea. Subjects with SEs has significantly higher plasma levels of farampator than subjects without SEs.
安全信息
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024/08/19 | HY-10937 | Farampator | 1 mg | 453元 | |
2024/08/19 | HY-10937 | CX691 Farampator | 211735-76-1 | 5mg | 900元 |